环磷酰胺可改善接受单倍体相合外周血干细胞移植的伴严重器官损伤的镰状细胞病患者植入
该1/2期试验采用阿仑单抗、400 cGy全身照射及递增剂量移植后环磷酰胺(PT-Cy)方案,对21例镰状细胞病和2例β-地中海贫血患者进行非清髓性单倍体相合外周血干细胞移植。植入率从第1队列的1/3(33%)提高至第2队列的5/8(63%)和第3队列的10/12(83%),无移植相关死亡,总生存率87%,且无2-4级急性或广泛慢性移植物抗宿主病。
要点
- PT-Cy递增剂量(0、50、100 mg/kg)使植入率从33%提高至63%和83%。
- 无移植相关死亡,总生存率87%,无2-4级急性或广泛慢性GVHD。
- 目前无病生存率第1队列0%、第2队列25%、第3队列50%。
核心结论
- PT-Cy可改善高危镰状细胞病患者非清髓性单倍体相合外周血干细胞移植后的植入,并成功预防严重GVHD。
- 仍需额外策略以降低移植物排斥率,实现广泛可及的治愈。
研究设计与样本
- 基于临床前模型发现的1/2期试验,采用阿仑单抗、400 cGy全身照射及递增剂量移植后环磷酰胺(PT-Cy):第1队列0 mg/kg、第2队列50 mg/kg、第3队列100 mg/kg。
- 共21例镰状细胞病和2例β-地中海贫血患者接受移植,平均造血干细胞移植特异性合并症指数为6,反映患者存在肝硬化、心力衰竭和终末期肾病。
主要发现
- 植入率从第1队列的1/3(33%)提高至第2队列的5/8(63%)和第3队列的10/12(83%)。
- 供者髓系和CD3嵌合率随后续队列亦改善。
- 无移植相关死亡,总生存率为87%。
- 目前无病生存率第1队列0%、第2队列25%、第3队列50%。
- 无2-4级急性或广泛慢性移植物抗宿主病(GVHD)。
局限性
- 仍需额外策略以降低移植物排斥率并实现广泛可及的治愈。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Peripheral blood stem cell transplantation (PBSCT) offers a curative option for sickle cell disease (SCD). Although HLA-matched sibling transplantation is promising, the vast majority of patients lack such a donor. We sought to develop a novel nonmyeloablative HLA-haploidentical PBSCT approach that could safely be used for patients with severe organ damage. Based on findings in our preclinical model, we developed a phase 1/2 trial using alemtuzumab, 400 cGy total body irradiation, and escalating doses of posttransplant cyclophosphamide (PT-Cy): 0 mg/kg in cohort 1, 50 mg/kg in cohort 2, and 100 mg/kg in cohort 3. A total of 21 patients with SCD and 2 with β-thalassemia received a transplant. The mean hematopoietic cell transplant-specific comorbidity index of 6 reflected patients with cirrhosis, heart failure, and end-stage renal disease. The engraftment rate improved from 1 (33%) of 3 in cohort 1 to 5 (63%) of 8 in cohort 2 and 10 (83%) of 12 in cohort 3. Percentage of donor myeloid and CD3 chimerism also improved with subsequent cohorts. There was no transplant-related mortality, and overall survival was 87%. At present, 0% in cohort 1, 25% in cohort 2, and 50% in cohort 3 remain free of their disease. There was no grade 2 to 4 acute or extensive chronic graft-versus-host disease (GVHD). Therefore, PT-Cy improves engraftment and successfully prevents severe GVHD after nonmyeloablative conditioning in patients with SCD who are at high risk for early mortality. Additional strategies are necessary to decrease the graft rejection rate and achieve a widely available cure for all patients with SCD. This trial was registered at www.clinicaltrials.gov as #NCT00977691.
引用
- Fitzhugh CD, Hsieh MM, Taylor T, et al. Cyclophosphamide improves engraftment in patients with SCD and severe organ damage who undergo haploidentical PBSCT. Blood Adv. 2017. PMID: 29296707. doi:10.1182/bloodadvances.2016002972
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。